[1] |
Lichtenberger BM, Gerber PA, Holcmann M, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation[J]. Sci Transl Med, 2013, 5(199): 199ra111. DOI: 10.1126/scitranslmed.3005886.
|
[2] |
Fakih M, Vincent M. Adverse events associated with anti⁃EGFR therapies for the treatment of metastatic colorectal cancer[J]. Curr Oncol, 2010, 17 Suppl 1: S18⁃30.
|
[3] |
Madke B, Gole P, Kumar P, et al. Dermatological side effects of epidermal growth factor receptor inhibitors: 'PRIDE' complex[J]. Indian J Dermatol, 2014, 59(3): 271⁃274. DOI: 10.4103/0019⁃5154.131398.
|
[4] |
Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane[J]. J Am Acad Dermatol, 2015, 72(2): 203⁃218. DOI: 10.1016/j.jaad.2014.07.032.
|
[5] |
Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors[J]. Ann Oncol, 2005, 16(9): 1425⁃1433. DOI: 10.1093/annonc/mdi279.
|
[6] |
Severino G, Chillotti C, De Lisa R, et al. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors[J]. Ann Pharmacother, 2005, 39(1): 162⁃164. DOI: 10.1345/aph.1E127.
|
[7] |
Basso FG, Boer CC, Corrêa ME, et al. Skin and oral lesions associated to imatinib mesylate therapy[J]. Support Care Cancer, 2009, 17(4): 465⁃468. DOI: 10.1007/s00520⁃008⁃0536⁃8.
|
[8] |
Reyes⁃Habito CM, Roh EK. Cutaneous reactions to chemothera⁃peutic drugs and targeted therapy for cancer: Part II. Targeted therapy[J/OL]. J Am Acad Dermatol, 2014, 71(2): 217.e1⁃217.e11[2015⁃07⁃16]. DOI: 10.1016/j.jaad.2014.04.013. http://www.jaad.org/article/S0190⁃9622(14)01363⁃2/pdf.
|
[9] |
Li CC, Malik SM, Blaeser BF, et al. Mucosal pigmentation caused by imatinib: report of three cases[J]. Head Neck Pathol, 2012, 6(2): 290⁃295. DOI: 10.1007/s12105⁃011⁃0325⁃4.
|
[10] |
Bois E, Holle LM, Farooq U. Late onset imatinib⁃induced Stevens⁃Johnson syndrome[J]. J Oncol Pharm Pract, 2014, 20(6): 476⁃478. DOI: 10.1177/1078155213518226.
|
[11] |
Llamas⁃Velasco M, Steegmann JL, Carrascosa R, et al. Perforating folliculitis in a patient treated with nilotinib: a further evidence of C⁃kit involvement[J]. Am J Dermatopathol, 2014, 36(7): 592⁃593. DOI: 10.1097/DAD.0b013e31828cf3b7.
|
[12] |
Ishak RS, Aad SA, Kyei A, et al. Cutaneous manifestations of anti⁃angiogenic therapy in oncology: Review with focus on VEGF inhibitors[J]. Crit Rev Oncol Hematol, 2014, 90(2): 152⁃164. DOI: 10.1016/j.critrevonc.2013.11.007.
|
[13] |
Kiuru M, Schwartz M, Magro C. Cutaneous thrombogenic vasculo⁃pathy associated with bevacizumab therapy[J/OL]. Dermatol Online J, 2014, 20(6): 9. [2015⁃08⁃18]. http://escholarship.org/uc/item/41f655g9.
|
[14] |
Farber SA, Samimi S, Rosenbach M. Ulcerations within striae distensae associated with bevacizumab therapy[J]. J Am Acad Dermatol, 2015, 72(1): e33⁃e35. DOI: 10.1016/j.jaad.2014.09. 023.
|
[15] |
Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib[J]. Br J Dermatol, 2009, 161(5): 1045⁃1051. DOI: 10.1111/j.1365⁃2133.2009.09290.x.
|
[16] |
Blanchet B, Billemont B, Barete S, et al. Toxicity of sorafenib: clinical and molecular aspects[J]. Expert Opin Drug Saf, 2010, 9(2): 275⁃287. DOI: 10.1517/14740330903510608.
|
[17] |
Boers⁃Doets CB, Epstein JB, Raber⁃Durlacher JE, et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review[J]. Oncologist, 2012, 17(1): 135⁃144. DOI: 10.1634/theoncologist.2011⁃0111.
|
[18] |
Robert C, Spatz A, Faivre S, et al. Tyrosine kinase inhibition and grey hair[J]. Lancet, 2003, 361(9362): 1056. DOI: 10.1016/S0140⁃6736(03)12805⁃X.
|
[19] |
McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib[J]. Dermatol Ther, 2011, 24(4): 396⁃400. DOI: 10.1111/j.1529⁃8019.2011.01435.x.
|
[20] |
Jiménez⁃Gallo D, Albarrán⁃Planelles C, Linares⁃Barrios M, et al. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib[J]. JAMA Dermatol, 2013, 149(5): 624⁃626. DOI: 10.1001/jamadermatol.2013.263.
|
[21] |
Eaby⁃Sandy B, Grande C, Viale PH. Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors[J]. J Adv Pract Oncol, 2012, 3(3): 138⁃150.
|
[22] |
Shimizu T, Tolcher AW, Papadopoulos KP, et al. The clinical effect of the dual⁃targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer[J]. Clin Cancer Res, 2012, 18(8): 2316⁃2325. DOI: 10.1158/1078⁃0432.CCR⁃11⁃2381.
|
[23] |
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation[J]. N Engl J Med, 2011, 364(26): 2507⁃2516. DOI: 10.1056/NEJMoa1103782.
|
[24] |
Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600⁃mutant advanced melanoma treated with vemurafenib[J]. N Engl J Med, 2012, 366(8): 707⁃714. DOI: 10.1056/NEJMoa1112302.
|
[25] |
Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors[J]. J Clin Oncol, 2012, 30(3): 316⁃321. DOI: 10.1200/JCO.2011.36.7680.
|
[26] |
Chu EY, Wanat KA, Miller CJ, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study[J]. J Am Acad Dermatol, 2012, 67(6): 1265⁃1272. DOI: 10.1016/j.jaad.2012.04.008.
|
[27] |
Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways[J]. J Am Acad Dermatol, 2015, 72(2): 221⁃236. DOI: 10.1016/j.jaad.2014.07.033.
|
[28] |
Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy[J]. N Engl J Med, 2012, 366(5): 480⁃481. DOI: 10.1056/NEJMc1113752.
|
[29] |
Huang V, Hepper D, Anadkat M, et al. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway[J]. Arch Dermatol, 2012, 148(5): 628⁃633. DOI: 10.1001/archdermatol.2012.125.
|
[30] |
Lim HJ, Crowe P, Yang JL. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer[J]. J Cancer Res Clin Oncol, 2015, 141(4): 671⁃689. DOI: 10.1007/s00432⁃014⁃1803⁃3.
|
[31] |
Campistol JM, de Fijter JW, Flechner SM, et al. mTOR inhibitor⁃associated dermatologic and mucosal problems[J]. Clin Transplant, 2010, 24(2): 149⁃156. DOI: 10.1111/j.1399⁃0012.2010.01232.x.
|
[32] |
Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib[J]. J Am Acad Dermatol, 2014, 70(1): 60⁃69. DOI: 10.1016/j.jaad.2013.09.012.
|
[33] |
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma[J]. N Engl J Med, 2011, 364(26): 2517⁃2526. DOI: 10.1056/NEJMoa1104621.
|
[34] |
Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti⁃PD⁃1) in melanoma[J]. N Engl J Med, 2013, 369(2): 134⁃144. DOI: 10.1056/NEJMoa1305133.
|